Riskpilot← Back to searchSign inGet full accessBiofiltration Nordic Oy
OYDissolvedY-tunnus 2642586-7Ensontie 45-B15Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2014— employees
Revenue 2025
EUR 0
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2025
EUR 0
| Revenue | EUR 0 | — |
| EBITDA | EUR 0 | — |
| Net profit | EUR 0 | — |
| Total assets | EUR 0 | — |
| Equity | EUR -26K | +0% |
| Employees | — | — |
Legal name
Biofiltration Nordic Oy
Y-tunnus number
2642586-7
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
19. syyskuuta 2014
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Palvelut ja tarvikkeet teollisuuden, terveydenhuollon ja kotitalouden veden- ja ilman puhdistukseen sekä kaikki muu laillinen toiminta
Address
Ensontie 45-B15
Phone
+358468837694
Email
biofiltration.nordic.oy@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12 | 4 | 0 | 0 | 0 |
| Staff expenses | −3 | −0 | −0 | −0 | −0 |
| EBITDA | −7 | 3 | 4 | 0 | 0 |
| Depreciation & amort. | — | −0 | −0 | −0 | −0 |
| EBIT | −7 | 3 | 4 | 0 | 0 |
| Net financials | −1 | 0 | 0 | 0 | 0 |
| Profit before tax | −8 | 3 | 4 | 0 | 0 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −8 | 3 | 4 | 0 | 0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 | 381 | 9 | 0 | 0 |
| Equity | −59 | −30 | −26 | −26 | −26 |
| Long-term debt | 45 | 0 | 0 | 0 | 0 |
| Short-term debt | 15 | 3 420 | 35 | 26 | 26 |
| Total debt | 59 | 3 420 | 35 | 26 | 26 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20212025
Equity ratio
-2635000.0%
This company
38.2%
Market median
-6898006% vs market
20212025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via PRH / YTJ · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via PRH / YTJ · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
VV Deputy Member | Deputy Member | 2024 |
| Former (2) | ||
AK Chief Executive Officer | Chief Executive Officer | 2019 – 2022 |
AK Chief Executive Officer | Chief Executive Officer | 2014 – 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2024 | |
| Former (3) | ||
| Chairperson | 2014 – 2024 | |
| Board of Directors | 2014 – 2024 | |
| Board of Directors | 2014 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Biofiltration Nordic Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anastasia Khavanskaya | Chief Executive Officer | 0 companies |
| Vladimir Vinogradov | Deputy Member | 0 companies |
| Anastasia Khavanskaya | Chief Executive Officer | 0 companies |
| Massimo Alghisi | Chairperson | 0 companies |
| Natalia Vinogradova | Board of Directors | 0 companies |
| Natalia Gaponova | Board of Directors | 0 companies |
| Natalia Vinogradova | Board of Directors | 0 companies |